
JNJ Stock Forecast & Price Target
JNJ Analyst Ratings
Bulls say
Johnson & Johnson has demonstrated a significant acceleration in revenue growth, moving from 3-4% between 2016 and 2019 to 6.1% in 2022 and further to 7.8% in 2023, underpinned by innovation and a focused approach to its pharmaceutical and medical device divisions. The company's promising product pipeline, particularly with advancements in therapies such as Tremfya, Erleada, and Spravato, positions it favorably for continued momentum in revenue generation and market recognition. Furthermore, JNJ is seen as attractively valued, maintaining historical multiples while benefiting from a strengthened financial profile following the divestment of its consumer business in 2023.
Bears say
Johnson & Johnson's stock outlook is negatively impacted by anticipated challenges in organic revenue growth, specifically due to a potential decline in contributions from its pharmaceutical pipeline and lost exclusivity for key drugs, which could limit revenues to below $57 billion by 2025. The company faces competitive pressures in its MedTech division that may hinder growth, in addition to the risks associated with mergers and acquisitions, ongoing litigation costs, and regulatory pressures from the Inflation Reduction Act and state-level prescription drug boards. Overall, these factors collectively contribute to a forecast of weaker financial performance and uncertainties surrounding future revenue stability.
This aggregate rating is based on analysts' research of Johnson & Johnson and is not a guaranteed prediction by Public.com or investment advice.
JNJ Analyst Forecast & Price Prediction
Start investing in JNJ
Order type
Buy in
Order amount
Est. shares
0 shares